Cian Healthcare Ltd Stock Price Today (NSE: CHCL)
Fundamental Score
Cian Healthcare Ltd Share Price — Live NSE/BSE Price, Fundamentals & Analysis
Cian Healthcare Ltd share price today is ₹73.03, up +0.00% on NSE/BSE as of 30 March 2026. Cian Healthcare Ltd (CHCL) is a Small-cap company in the Pharmaceuticals sector with a market capitalisation of ₹14.60 (Cr). The 52-week high for CHCL share price is ₹73.03 and the 52-week low is ₹2.99. The company has a Return on Equity (ROE) of -14.27% and a debt-to-equity ratio of 1.05.
Cian Healthcare Ltd Share Price Chart — NSE/BSE Historical Performance
Returns & Performance
ROE
ROCE
OPM (5Y)
Div Yield
Cian Healthcare Ltd Valuation Check
P/E Ratio
Industry P/E
Market Cap
Growth Engine
Profit Growth (Q)
Sales Growth (Q)
Sales Growth (5Y)
EPS Growth (5Y)
Profit Growth (5Y)
Balance Sheet Health
Debt to Equity
Int. Coverage
Free Cash Flow (5Y)
Shareholding
Promoter
FII
DII
Pledged
Institutional Deep-Dive
Bull Run Research Hub
Cian Healthcare Share Price: A Financial Analysis
One of the biggest challenges pharmaceutical companies face is maintaining profitability after patent expiration. Generics erode market share, forcing firms to continuously innovate. This analysis examines the financial health of Cian Healthcare Ltd, focusing on its current performance and comparing it to its peers. Currently, the Cian Healthcare share price stands at ₹5.01.
A key concern is the absence of a Price-to-Earnings (PE) ratio, typically a straightforward indicator of market valuation. The "None" value suggests either the company is not profitable, or its earnings are negligible. This necessitates deeper scrutiny of profitability metrics.
Return on Capital Employed (ROCE) paints a clearer picture. Cian Healthcare's ROCE of -5.7% indicates the company is destroying shareholder value, as it's not generating sufficient profit from its deployed capital. A negative ROCE fundamentally weakens the company's "moat," making it difficult to build sustainable competitive advantages, attract investors, or fund future growth initiatives. In contrast, consider
Mankind Pharma Ltd whose perceived management quality generally reflects stronger strategic execution and financial performance.Comparing Cian Healthcare to sector peers like Mankind Pharma Ltd, Smruthi Organics Ltd, and Balaxi Pharmaceuticals Ltd highlights relative underperformance. Further investigation into Cian Healthcare's debt levels, operational efficiency, and research & development pipeline is essential. A turnaround strategy will need to address fundamental issues before the company can achieve sustainable profitability and positive ROCE. This analysis is part of a larger, 80-parameter fundamental audit, independently verified by Sweta Mishra. It presents an observational view of publicly available financial data, and does not constitute investment advice.
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Cian Healthcare Ltd Fundamental Analysis & Valuation Benchmarking
Educational evaluation of CHCL across key market metrics for learning purposes.
Positive Indicators
1 factors identified
Strong Cash Generation (₹32.96 Cr over 5Y)
Observation: Healthy free cash flow generation supports growth and returns.
Analysis: Strong FCF provides flexibility for dividends, debt reduction, and growth investments.
Risk Factors
10 factors identified
Below-Average Return on Equity (-14.27%)
Observation: Returns on equity are below industry benchmarks.
Analysis: ROE <10% may indicate inefficient capital utilization. Consider monitoring for operational improvements and management effectiveness.
Suboptimal ROCE (-5.70%)
Observation: Returns on capital employed are below expectations.
Analysis: ROCE <10% suggests potential inefficiencies in capital allocation.
Profit Decline Concern (-20.75%)
Observation: Significant year-over-year profit contraction observed.
Analysis: Declining profitability requires investigation into underlying causes.
Revenue Contraction (-38.98%)
Observation: Sales decline may indicate market challenges or competitive pressures.
Analysis: Negative revenue growth requires analysis of market conditions.
Limited Growth History (-11.55% CAGR)
Observation: Below-average 5-year sales growth trajectory.
Analysis: Low sales CAGR may indicate mature markets or limited growth opportunities.
Elevated Debt Levels (D/E: 1.05)
Observation: High leverage increases financial risk and interest burden.
Analysis: High debt-to-equity ratios require monitoring of debt servicing capability.
Weak Interest Coverage (-133.33x)
Observation: Limited ability to service debt obligations from earnings.
Analysis: Low interest coverage raises concerns about financial stability.
Low Promoter Commitment (27.11%)
Observation: Reduced promoter stake may indicate limited confidence.
Analysis: Low promoter holding may raise questions about management commitment.
High Share Pledging Risk (34.48%)
Observation: Significant promoter share pledging creates potential overhang.
Analysis: High pledging levels may create selling pressure during market downturns.
No Dividend Distribution
Observation: Company does not currently pay dividends to shareholders.
Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints.
Cian Healthcare Ltd Financial Statements
Comprehensive financial data for Cian Healthcare Ltd including income statement, balance sheet and cash flow
About CHCL (Cian Healthcare Ltd)
Cian Healthcare Ltd is a dynamic pharmaceutical company dedicated to improving lives through innovative healthcare solutions. Operating primarily in India, CHCL focuses on the enti...re lifecycle of drug development, from rigorous research and meticulous development to efficient manufacture and strategic marketing. The company prides itself on its commitment to quality and patient well-being, striving to provide accessible and affordable medications that address a wide spectrum of health needs. CHCL aims to be a trusted partner for healthcare professionals and patients alike, driven by a mission to enhance the quality of life through pharmaceutical excellence. CHCL's product portfolio reflects its comprehensive approach to healthcare, encompassing a diverse range of therapeutic areas. From specialized treatments in gynecology and critical cardio-diabetic medications to essential orthopedic and pediatric formulations, CHCL caters to the varied needs of a growing population. The company also recognizes the increasing importance of preventative care, offering a range of vitamins, nutrients, and dermacosmetic products designed to promote overall health and well-being. With a commitment to addressing evolving healthcare challenges, CHCL continuously expands its product offerings through active research and strategic collaborations. Beyond traditional pharmaceuticals, Cian Healthcare Ltd acknowledges and addresses specific unmet medical needs within the community. This proactive approach is exemplified through their commitment to providing specialized products in areas such as male and female infertility, contributing to reproductive wellness. Furthermore, the company recognizes the importance of cognitive health and offers products aimed at energy boosting and supporting individuals with autism. By focusing on these crucial areas, CHCL demonstrates a dedication to comprehensive healthcare and a commitment to improving the lives of individuals across diverse demographics and needs.
Company Details
Key Leadership
Latest News
CHCL Share Price: Frequently Asked Questions
What is the current share price of Cian Healthcare Ltd (CHCL)?
As of 30 Mar 2026, 11:00 am IST, Cian Healthcare Ltd share price is ₹73.03. The CHCL stock has a market capitalisation of ₹14.60 (Cr) on NSE/BSE.
Is CHCL share price Overvalued or Undervalued?
CHCL share price is currently trading at a P/E ratio of 0.00x, compared to the industry average of 31.77x. Based on this relative valuation, the Cian Healthcare Ltd stock appears to be Fairly Valued against its sector peers.
What is the 52-week high and low of CHCL share price?
The 52-week high of CHCL share price is ₹73.03 and the 52-week low is ₹2.99. These values are updated daily from NSE/BSE price data.
What factors affect the Cian Healthcare Ltd share price?
Key factors influencing CHCL share price include quarterly earnings growth (Sales Growth: -38.98%), raw material costs, government infrastructure spending, and institutional flows (FII/DII holding).
Is Cian Healthcare Ltd a good stock for long-term investment?
Cian Healthcare Ltd shows a 5-year Profit Growth of N/A% and an ROE of -14.27%. Long-term investors should consider these fundamentals alongside the debt-to-equity ratio of 1.05 before investing in CHCL shares.
How does Cian Healthcare Ltd compare with its industry peers?
Cian Healthcare Ltd competes with major peers in the Pharmaceuticals. Investors should compare CHCL share price P/E of 0.00x and ROE of -14.27% against the industry averages to determine competitive standing.
What is the P/E ratio of CHCL and what does it mean?
CHCL share price has a P/E ratio of N/Ax compared to the industry average of 31.77x. Investors pay ₹N/A for every ₹1 of annual earnings.
How is CHCL performing according to Bull Run's analysis?
CHCL has a Bull Run fundamental score of N/A/100, indicating concerns requiring careful analysis. This comprehensive rating is based on 15+ financial parameters.
What sector and industry does CHCL belong to?
CHCL operates in the Pharmaceuticals industry. This classification helps understand the competitive landscape and sector-specific trends affecting Cian Healthcare Ltd share price.
What is Return on Equity (ROE) and why is it important for CHCL?
CHCL has an ROE of -14.27%, which suggests challenges in generating returns from shareholders equity. ROE measures how efficiently Cian Healthcare Ltd generates profits from shareholders capital.
How is CHCL debt-to-equity ratio and what does it indicate?
CHCL has a debt-to-equity ratio of 1.05, which indicates high leverage that increases financial risk.
What is CHCL dividend yield and is it a good dividend stock?
CHCL offers a dividend yield of 0.00%, meaning you receive ₹0.00 annual dividend for every ₹100 invested in Cian Healthcare Ltd shares.
How has CHCL share price grown over the past 5 years?
CHCL has achieved 5-year growth rates of: Sales Growth -11.55%, Profit Growth N/A%, and EPS Growth N/A%.
What is the promoter holding in CHCL and why does it matter?
Promoters hold 27.11% of CHCL shares, with 34.48% pledged. High promoter holding often indicates strong management confidence in Cian Healthcare Ltd.
What is CHCL market capitalisation category?
CHCL has a market capitalisation of ₹15 crores, placing it in the Small-cap category.
How volatile is CHCL stock?
CHCL has a beta of N/A. A beta > 1 suggests the Cian Healthcare Ltd stock is more volatile than the market, while a beta < 1 suggests it is less volatile.
What is CHCL operating profit margin trend?
CHCL has a 5-year average Operating Profit Margin (OPM) of 9.63%, indicating the company's operational efficiency.
How is CHCL quarterly performance?
Recent quarterly performance shows Cian Healthcare Ltd YoY Sales Growth of -38.98% and YoY Profit Growth of -20.75%.
What is the institutional holding pattern in CHCL?
CHCL has FII holding of 0.00% and DII holding of 0.00%. Significant institutional holding often suggests professional confidence in the Cian Healthcare Ltd stock.